Modified anti-EGFR antibodies with reduced immunogenicity
US7132511B2 · kind B2 · utility
33Cited by
3References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2002 |
| Grant date | Nov 7, 2006 |
| Priority date | — |
| Expiry date | Jan 20, 2023 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B20/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.